Ariel Guo

Vice President, BD / Chief of Staff at Antengene Corporation Limited

Presenter

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of “Treating Patients Beyond Borders”. Late Stage Best-in-class Global Program ATG-022 (Claudin 18.2 ADC) - Efficacy across the widest patient population and the best safety profile without cumulative toxicities, allowing for a longer treatment duration; Currently in Phase II and soon entering pivotal stage AnTenGager™ “2+1” T Cell Engager Platform with Steric Hindrance-masking Technology, Enabling Creation of TCEs with Enhanced Therapeutic Effect and Safety [OPEN FOR PARTNERING] Partnering Options: - Platform Access (Bring Your Own Antibody and leverage the platform to generate or optimize novel TCEs) - Co-discovery/Co-development of novel innovative TCEs from the ground up - Licensing Existing Programs in our TCE Pipeline Differentiations: - “2+1” structure facilitates bivalent binding to the targets, enabling the detection and depletion of cells with low expression of the targets - “Steric hindrance” allows unique TAA-dependent CD3 binding and activation which mitigates risk of cytokine release syndrome - Masking is achieved through the low stiffness of the CD3 arm, which is NOT protease-dependent, does NOT rely on the tumor microenvironment (TME) to be effective and function effectively in both cancer and non-cancer disease settings - In-house developed proprietary CD3 sequences with diverse affinities, targeting a unique conformational epitope on CD3 that expressed on T-cells TCE Pipeline: - ATG-201 (CD19 x CD3) for B Cell Related Autoimmune Diseases: Preclinical studies demonstrated superior efficacy and reduced risk of cytokine release syndrome compared with BMKs; IND-enabling and CMC work is on-go